Urologix Sponsors Residency Education at the Western AUA Meeting

Urologix Sponsors Residency Education at the Western AUA Meeting

Urologix will sponsor the course, "Surviving After Residency -- Learning the
Business Side of the Practice", which is designed to bridge the gap between
urology residents and successful physician practice management.

MINNEAPOLIS, Minn., Oct. 30, 2013 (GLOBE NEWSWIRE) -- via PRWEB - Urologix®,
Inc. (OTCQB:ULGX), the market leader for In-Office BPH Therapy, will sponsor a
residency education program at the upcoming 89th Annual Meeting of the Western
Section of the American Urological Association (AUA). The sectional meeting is
being held at the Portola Hotel in Monterey, California from November 3-7,
2013. The course, "Surviving After Residency – Learning the Business Side of
the Practice", is designed to bridge the gap between urology residents and
successful physician practice management.

This program will focus on helping residents understand how to incorporate
minimally invasive therapies into their practice, debate the current standards
of care in urology, describe the differences in HMO, private practice, and
academic positions, and analyze the current and changing financial and medical
landscapes. The course will include lecture, panel, and discussion groups and
be taught by a panel of experts led by program chairman, Jonathan Perley, MD,
Medical Director at California Urology. The panel will also include Drs.
Eugene Rhee from Kaiser Permanente, David Josephson from Tower Urology, and
Mark Edney from Peninsula Urology Associates. The course will take place on
Sunday, November 3rd from 11:15 AM PT until 1:15 PM PT in the Ironwood Room,
and all residents in attendance at the WSAUA Annual Meeting are invited to
attend at no charge.

"There is a known gap between the excellent clinical education we give our
residents and the skills and knowledge needed to run a professional practice,
and that gap is widening as healthcare economics becomes more and more
complicated." stated Dr. Perley, Program Chairman. "This course is designed to
give residents critical practice management information to narrow that gap and
assist with their transition from residency to private practice."

Urologix will also host an unmoderated poster presentation by Dr. Parminder
Sethi on Sunday, November 3rd. Dr. Sethi is coauthor of the accepted abstract:
"Prostiva® RF Therapy for BPH: A Retrospective Analysis of Single‐Center
Outcomes." and the poster describes his patients' clinical outcomes using
Urologix' Prostiva® RF Therapy.

Urologix provides urologists with two effective and durable minimally invasive
BPH treatment options – Cooled ThermoTherapy™ and Prostiva® RF Therapy. Both
procedures have proven their results through numerous clinical studies and are
included within the AUA BPH Treatment Guidelines. These therapies can be
performed in the urologist's office in less than an hour providing an
excellent, cost-effective BPH treatment option for both urologists and their
patients. Visit http://www.urologix.com to learn more about BPH and In-Office
BPH Therapy and discover why it is as an excellent alternative to chronic
medication therapy.

About Urologix

Urologix, Inc., based in Minneapolis, develops, manufactures, markets and
distributes minimally invasive medical products for the treatment of
obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). Urologix'
Cooled ThermoTherapy™ produces targeted microwave energy combined with a
unique cooling mechanism to protect healthy tissue and enhance patient
comfort. The Prostiva® RF Therapy System is an anatomical approach which uses
radio frequency energy to destroy the prostate tissue, reducing constriction
of the urethra, and thereby relieving BPH symptoms. Both of these therapies
provide safe, effective and lasting relief of obstruction and symptoms due to
BPH. Prostiva is a registered trademark of Medtronic, Inc., used under
license. All other trademarks are the property of Urologix.

Federal USA law restricts these devices to sale by or on the order of a
physician. For more complete information about the benefits, risks and
contraindications associated with Cooled ThermoTherapy and Prostiva RF
Therapy, please refer to http://www.urologix.com.

If you would like more information on this topic, please contact Karen Snay at
513-484-2987 or ksnay(at)urologix(dot)com.

The Urologix logo and other media assets are available at
http://www.urologix.com/clinicians/resource-library.php.

Urologix Media Contact

Karen Snay

(513) 484-2987

Ksnay(at)urologix(dot)com

Urologix Investor Relations Contact
Brian Smrdel

(763) 475-7696

Bsmrdel(at)urologix(dot)com

This article was originally distributed on PRWeb. For the original version
including any supplementary images or video, visit
http://www.prweb.com/releases/2013/10/prweb11279768.htm

CONTACT: Urologix, Inc.
         Karen Snay
         ksnay@urologix.com
         +1 5134842987
 
Press spacebar to pause and continue. Press esc to stop.